New painkiller aims to ease Post-Surgery pain without stomach upset

NCT ID NCT07637968

Not yet recruiting Symptom relief Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a newer painkiller, tegileridine, can control pain after major laparoscopic abdominal surgery as well as the standard drug sufentanil, but with fewer gastrointestinal side effects like nausea or constipation. About 84 adults having elective major abdominal surgery will receive one of the two drugs through a patient-controlled pump after surgery. The main goal is to see if tegileridine provides better gut tolerance while keeping pain scores low.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tegileridine
What this could lead to: If tegileridine works as hoped, it could offer a painkiller option after abdominal surgery that is gentler on the stomach and bowels while still controlling pain effectively.
What could go wrong: This is a small, early-phase trial (84 people) comparing two drugs, so results may not apply to everyone. Tegileridine might not prove better or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTOPERATIVE PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTOPERATIVE PAIN

More trials for these conditions

Other studies related to the condition(s) this trial covers.